Cargando…
Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy
BACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071779/ https://www.ncbi.nlm.nih.gov/pubmed/27760685 http://dx.doi.org/10.7448/IAS.19.7.21108 |
_version_ | 1782461328709910528 |
---|---|
author | Cáceres, Carlos F Borquez, Annick Klausner, Jeffrey D Baggaley, Rachel Beyrer, Chris |
author_facet | Cáceres, Carlos F Borquez, Annick Klausner, Jeffrey D Baggaley, Rachel Beyrer, Chris |
author_sort | Cáceres, Carlos F |
collection | PubMed |
description | BACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. DISCUSSION: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive “combination prevention” programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. CONCLUSIONS: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers’ openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation. |
format | Online Article Text |
id | pubmed-5071779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-50717792016-10-27 Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy Cáceres, Carlos F Borquez, Annick Klausner, Jeffrey D Baggaley, Rachel Beyrer, Chris J Int AIDS Soc Commentary BACKGROUND: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries. DISCUSSION: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive “combination prevention” programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand. CONCLUSIONS: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers’ openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation. International AIDS Society 2016-10-18 /pmc/articles/PMC5071779/ /pubmed/27760685 http://dx.doi.org/10.7448/IAS.19.7.21108 Text en © 2016 Cáceres CF et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Cáceres, Carlos F Borquez, Annick Klausner, Jeffrey D Baggaley, Rachel Beyrer, Chris Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title | Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title_full | Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title_fullStr | Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title_full_unstemmed | Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title_short | Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
title_sort | implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071779/ https://www.ncbi.nlm.nih.gov/pubmed/27760685 http://dx.doi.org/10.7448/IAS.19.7.21108 |
work_keys_str_mv | AT cacerescarlosf implementationofpreexposureprophylaxisforhumanimmunodeficiencyvirusinfectionprogressandemergingissuesinresearchandpolicy AT borquezannick implementationofpreexposureprophylaxisforhumanimmunodeficiencyvirusinfectionprogressandemergingissuesinresearchandpolicy AT klausnerjeffreyd implementationofpreexposureprophylaxisforhumanimmunodeficiencyvirusinfectionprogressandemergingissuesinresearchandpolicy AT baggaleyrachel implementationofpreexposureprophylaxisforhumanimmunodeficiencyvirusinfectionprogressandemergingissuesinresearchandpolicy AT beyrerchris implementationofpreexposureprophylaxisforhumanimmunodeficiencyvirusinfectionprogressandemergingissuesinresearchandpolicy |